Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer ...

As bars and restaurants across the globe contemplate how to safely serve diners during the pandemic, many establishments are seeking ways to reduce the number of touchpoints between servers and guests ...

Bbot, the hospitality tech provider that focuses on digital ordering and payments for restaurants, has agreed to be acquired by DoorDash to expand its service offering to merchants. The terms of the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

BBO-11818’s selectivity for KRAS demonstrated by its >1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell lines Efficacy of the combination with BBOT’s RAS:PI3K⍺ breaker, BBO-10203, is ...

DoorDash is acquiring Bbot, a hospitality technology startup. The acquisition will offer merchants more solutions for their in-store and online channels, including in-store digital ordering and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients ...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...